Drug Trial Radar · NCT07432854
A Clinical Study Evaluating the Efficacy and Safety of CMS-D001 Tablets in the Treatment of Adult Patients With Moderate to Severe Plaque-type Psoriasis
Last checked: Nov 19, 2026Latest source record: Feb 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
540
Planned (sponsor's estimate)
Start
Mar 3, 2026
Primary completion
Feb 29, 2028
Study completion Jul 30, 2028
Sponsor
- Lead sponsor
- Dermavon Holdings LimitedIndustry
- Sponsor type
- Industry
- First posted
- Feb 25, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study adopted a multicenter, randomized, double-blind, placebo-controlled phase II/III operation seamless adaptive design, aiming to evaluate the efficacy, safety and tolerability of CMS-D001 tablets in the treatment of patients with moderate to severe plaque psoriasis. The trial consists of two parts, including the Phase II clinical research stage and the Phase III clinical research stage.
Conditions
- Moderate to Severe Plaque Psoriasis
Interventions
CMS-D001 50mgDrug
CMS-D001 50mg QD
CMS-D001 100mgDrug
CMS-D001 100mg QD
PlaceboDrug
Placebo QD
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase Ⅱ:Number of participants achieving at least 75% improvement in Psoriasis Area and Severity Index (PASI 75)Time frame: At week 12
- Phase Ⅲ:Number of participants achieving at least 75% improvement in Psoriasis Area and Severity Index (PASI 75)Time frame: At week 16
- Phase Ⅲ:Number of participants achieving a Physician Global Assessment (PGA) score of 0 (clear) or 1 (almost clear) (PGA-TS)Time frame: At week 16
Locations
21 sites in 1 country. Site status is shown where the registry gives one.
Beijing Tongren Hospital Affiliated to Capital Medical University
Beijing, China
Shanghai Dermatology Hospital
Shanghai, China
The First Affiliated Hospital of Bengbu Medical College
Bengbu, Anhui, China
The First Affiliated Hospital of Wannan Medical College (Yijishan)
Wuhu, Anhui, China
Southern Medical University Dermatology Hospital
Guangzhou, Guangdong, China
Zhujiang Hospital of Southern Medical University
Guangzhou, Guangdong, China
Affiliated Hospital of Chengde Medical College
Chengde, Hebei, China
Affiliated Hospital of Hebei University of Engineering
Handan, Hebei, China
Shijiazhuang Traditional Chinese Medicine Hospital
Shijiazhuang, Hebei, China
The Fourth Affiliated Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
The Second Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China
Nanyang Central Hospital
Nanyang, Henan, China
Sanmenxia Central Hospital
Sanmenxia, Henan, China
Henan Provincial People's Hospital
Zhengzhou, Henan, China
Wuxi Second People's Hospital
Wuxi, Jiangsu, China
The First Hospital of Jilin University
Changchun, Jilin, China
Jining First People's Hospital
Jining, Shandong, China
Shandong First Medical University Affiliated Dermatology Hospital
Jinan, Shangdong, China
Hangzhou First People's Hospital
Hangzhou, Zhejiang, China
Hangzhou Third People's Hospital
Hangzhou, Zhejiang, China
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.